Suit Claims Illumina's Sequencer Infringes DNA Amplification Patent | GenomeWeb

NEW YORK (GenomeWeb News) – A suit filed in the US District Court for the District of Delaware today claims that Illumina's Genome Analyzer and related products and services infringe a patent originally issued to Genelabs and now held by a firm called LadaTech.

According to court documents, LadaTech has accused Illumina of infringing US Patent 6,107,023, "DNA Amplification and Subtraction Techniques," which was issued in 2000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.